Cefpodoxime Proxetil associated bloody diarrhoea, itching and red rashes in child: A case report
A case report of a five-year-old paediatric patient was presented here, who received Cefpodoxime proxetil for the treatment of Dengue fever and experienced bloody diarrhoea, itching and red rashes on hands. His laboratory data includes haemoglobin level 10.9 gm % (13-17 gm %), total leucocyte count 4100 /cmm (4000-1000 /cmm), neutrophils 73 % (40-75 %), lymphocytes 20 % (20-45 %), eosinophils 03 % (1-6 %), monocytes 04 % (2-10 %), platelet count 2.42 Lac /cµmm (1.5-4.5 Lac /cµmm), Lymph% 19.9 % (20-45), Gran% 72.5 % (40-75), HGB 10.9/103 /µL (11.0-16.0), HCT 34.9 % (37-54), MCV 68.1 fL (80-100), MCH 21.2 pg, MCHC 31.0 g /dL, RDW-CV 16.2 %, anti-Dengue-IgG and IgM tests are non-reactive and Dengue NS1 antigen test is weakly reactive. The patient recovered from red rashes and bloody diarrhoea after treatment discontinuation. Events bloody diarrhoea and red rashes are probably due to Cefpodoxime Proxetil treatment as per WHO causality assessment.
Fulton B, Perry CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. Paediatric Drugs, 2001;3(2):137- 58.
Gawai PP. Introduction and evaluation of Pharmacovigilance for beginners. International Journal of Scientific Reports, 2020;6(10):425-32.
Kim MH, Lee JM. Diagnosis and management of immediate hypersensitivity reactions to cephalosporins. Allergy Asthma & Immunology Research, 2014;6(6):485-95.
Rehan HS, Chopra D, Kakkar A. Physician's guide to pharmacovigilance: Terminology and causality assessment. European Journal of Internal Medicine, 2009; 20: 3-8.
Hasan S, Jamdar SF, Alalowi M, Beaiji SMAA. Journal of International Society of Preventive and Community Dentistry, 2016 Jan-Feb; 6(1):1-6.
World Health Organization (WHO) Dengue and severe dengue https://www.who.int/news-room/fact- sheets/detail/dengue-and-severe-dengue.
World Health Organization (WHO), Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment. Available from: https://www.who.int/medicines/areas/quality_safety/sa fety_efficacy/WHOcausality_assessment.pdf.
Copyright (c) 2021 Pushpraj Prafulla Gawai
This work is licensed under a Creative Commons Attribution 4.0 International License.